Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
13 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) | aurora kinase inhibitor
Show Display Options
Rank Status Study
1 Completed Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkins Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: Aurora kinase inhibitor AT9283
2 Active, not recruiting Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Conditions: Adult B Acute Lymphoblastic Leukemia;   Adult T Acute Lymphoblastic Leukemia;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Chronic Lymphocytic Leukemia;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Nodal Marginal Zone Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   T-Cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vorinostat
3 Completed A Study of Alisertib (MLN8237) in Adult East Asian Patients With Advanced Solid Tumors or Lymphomas
Conditions: Advanced Solid Tumors;   Lymphomas
Intervention: Drug: Alisertib
4 Completed
Has Results
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
5 Completed MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Conditions: Diffuse Large B-Cell Lymphoma;   Transformed Follicular Lymphoma;   Mantle Cell Lymphoma;   Burkitt's Lymphoma
Intervention: Drug: Alisertib (MLN8237) + Rituximab + Vincristine
6 Completed Study of MLN8237 in Participants With Advanced Hematological Malignancies
Conditions: B-cell Follicular Lymphoma;   B-cell Marginal Zone Lymphoma;   Diffuse Large B-cell Lymphoma;   B-cell Mantle Cell Lymphoma;   B-cell Small Lymphocytic Lymphoma (SLL);   B-Cell Chronic Lymphocytic Leukemia (B-CLL);   Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS);   Angioimmunoblastic T-cell Lymphoma (AITL);   Anaplastic Large Cell Lymphoma;   Enteropathy Associated T-cell Lymphoma (EATCL);   NK Lymphoma (NKL)
Intervention: Drug: Alisertib
7 Active, not recruiting Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: alisertib;   Biological: rituximab;   Other: laboratory biomarker analysis
8 Completed Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
Conditions: Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma;   Burkitt's Lymphoma;   Precursor B-lymphoblastic Leukemia/Lymphoma;   T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma;   Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component
Intervention: Drug: MLN8237
9 Not yet recruiting Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Conditions: CD30-positive Lymphoma;   CD30-positive Solid Tumor
Interventions: Drug: Brentuximab Vedotin;   Drug: Alsertib
10 Active, not recruiting Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Hepatoblastoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Kidney Neoplasm;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
11 Recruiting Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Drug: Alisertib;   Drug: Bortezomib;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab
12 Recruiting Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis;   Drug: Romidepsin
13 Terminated Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis
Intervention: Drug: AT9283

Study has passed its completion date and status has not been verified in more than two years.